Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. (Q44903950)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. |
scientific article |
Statements
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer (English)
Wolfgang J Köstler
Günther G Steger
Afschin Soleiman
Barbara Schwab
Christian F Singer
Sandra Tomek
Thomas Brodowicz
Christoph Wiltschke
Reinhard Horvat
Raimund Jakesz
Christoph C Zielinski